Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

TAPUR: Afprøvning af brugen af ​​Food and Drug Administration (FDA) godkendte lægemidler, der retter sig mod en specifik abnormitet i et tumorgen hos mennesker med kræft i avanceret stadium (TAPUR)

18. september 2026 opdateret af: American Society of Clinical Oncology

Undersøgelse af målrettet agent og profileringsanvendelse Registry (TAPUR).

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).

********************************************************************

Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.

********************************************************************

Studieoversigt

Detaljeret beskrivelse

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

4200

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Laurie Smith, MA
  • Telefonnummer: www.tapur.org
  • E-mail: tapur@asco.org

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35294
        • Rekruttering
        • University of Alabama at Birmingham Comprehensive Cancer Center
        • Ledende efterforsker:
          • Mehmet Akce, MD
        • Kontakt:
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85338
        • Rekruttering
        • Cancer Treatment Centers of America-Phoenix
        • Ledende efterforsker:
          • Sagun Shrestha, MD
        • Kontakt:
    • California
      • Auburn, California, Forenede Stater, 95602
        • Rekruttering
        • Sutter Auburn
        • Kontakt:
        • Ledende efterforsker:
          • Nitin Rohatgi, MD
      • Berkeley, California, Forenede Stater, 94705
        • Rekruttering
        • Sutter Alta Bates
        • Kontakt:
        • Ledende efterforsker:
          • Nitin Rohatgi, MD
      • Los Angeles, California, Forenede Stater, 90025
        • Rekruttering
        • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
        • Kontakt:
        • Ledende efterforsker:
          • Omid Hamid, MD
      • Oakland, California, Forenede Stater, 94611
        • Rekruttering
        • Kaiser Permanente - Oakland Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jennifer M Suga, MD
      • Palo Alto, California, Forenede Stater, 94301
      • Roseville, California, Forenede Stater, 95661
        • Rekruttering
        • Kaiser Permanente - Roseville Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jennifer M Suga, MD
      • Roseville, California, Forenede Stater, 95661
        • Rekruttering
        • Sutter Roseville
        • Kontakt:
        • Ledende efterforsker:
          • Nitin Rohatgi, MD
      • Sacramento, California, Forenede Stater, 95814
        • Rekruttering
        • Kaiser Permanente - Sacramento Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jennifer M Suga, MD
      • Sacramento, California, Forenede Stater, 95816
        • Rekruttering
        • Sutter Sacramento
        • Kontakt:
        • Ledende efterforsker:
          • Nitin Rohatgi, MD
      • San Francisco, California, Forenede Stater, 94115
        • Rekruttering
        • California Pacific Medical Center Research Institute
        • Kontakt:
        • Ledende efterforsker:
          • Nitin Rohatgi, MD
      • San Francisco, California, Forenede Stater, 94080
        • Rekruttering
        • Kaiser Permanente - South San Francisco Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jennifer M Suga, MD
      • San Francisco, California, Forenede Stater, 94115
        • Rekruttering
        • Kaiser Permanente - San Francisco Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jennifer M Suga, MD
      • San Francisco, California, Forenede Stater, 94115
        • Rekruttering
        • Sutter Cancer Research Consortium
        • Kontakt:
        • Ledende efterforsker:
          • Stacy D'Andre, MD
      • San Jose, California, Forenede Stater, 95119
        • Rekruttering
        • Kaiser Permanente - San Jose Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jennifer M Suga, MD
      • San Leandro, California, Forenede Stater, 94577
        • Rekruttering
        • Kaiser Permanente - San Leandro Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jennifer M Suga, MD
      • Santa Barbara, California, Forenede Stater, 93105
        • Rekruttering
        • Sutter Sansum Clinic
        • Ledende efterforsker:
          • Nitin Rohatgi, MD
        • Kontakt:
      • Santa Clara, California, Forenede Stater, 95051
        • Rekruttering
        • Kaiser Permanente - Santa Clara Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jennifer M Suga, MD
      • Santa Cruz, California, Forenede Stater, 95065
      • Santa Cruz, California, Forenede Stater, 994538
      • Sunnyvale, California, Forenede Stater, 94086
      • Vallejo, California, Forenede Stater, 94589
        • Rekruttering
        • Kaiser Permanente - Vallejo Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jennifer M. Suga, MD
      • Walnut Creek, California, Forenede Stater, 94596
        • Rekruttering
        • Kaiser Permanente - Walnut Creek Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jennifer M Suga, MD
    • Connecticut
      • Bridgeport, Connecticut, Forenede Stater, 06606
      • Hartford, Connecticut, Forenede Stater, 06102
      • Meriden, Connecticut, Forenede Stater, 06451
      • New Britain, Connecticut, Forenede Stater, 06053
        • Rekruttering
        • The Hospital of Central Connecticut (HOCC) Cancer Center
        • Ledende efterforsker:
          • Wylie Hosmer, MD
        • Kontakt:
      • Norwich, Connecticut, Forenede Stater, 06360
      • Torrington, Connecticut, Forenede Stater, 06790
      • Willimantic, Connecticut, Forenede Stater, 06226
    • Florida
      • Altamonte Springs, Florida, Forenede Stater, 32701
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Aventura, Florida, Forenede Stater, 33180
        • Rekruttering
        • University of Miami/Sylvester Cancer Institute - Aventura
        • Kontakt:
        • Ledende efterforsker:
          • Carmen Calfa, MD
      • Bonita Springs, Florida, Forenede Stater, 34135
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Bradenton, Florida, Forenede Stater, 34211
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Brandon, Florida, Forenede Stater, 33511
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Cape Coral, Florida, Forenede Stater, 33909
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Clearwater, Florida, Forenede Stater, 33761
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Coral Gables, Florida, Forenede Stater, 33146
        • Rekruttering
        • University of Miami/Sylvester Cancer Institute - Lennar
        • Kontakt:
        • Ledende efterforsker:
          • Carmen Calfa, MD
      • Deerfield Beach, Florida, Forenede Stater, 33442
        • Rekruttering
        • University of Miami/Sylvester Cancer Institute - Deerfield Beach
        • Kontakt:
        • Ledende efterforsker:
          • Carmen Calfa, MD
      • Fort Lauderdale, Florida, Forenede Stater, 33308
      • Fort Myers, Florida, Forenede Stater, 33901
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Fort Myers, Florida, Forenede Stater, 33905
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Fort Myers, Florida, Forenede Stater, 33908
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Gainesville, Florida, Forenede Stater, 32610
        • Rekruttering
        • University of Florida Health
        • Ledende efterforsker:
          • Thomas George, MD
        • Kontakt:
      • Gainesville, Florida, Forenede Stater, 32605
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Largo, Florida, Forenede Stater, 33770
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Lecanto, Florida, Forenede Stater, 34461
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Miami, Florida, Forenede Stater, 33136
        • Rekruttering
        • University of Miami Sylvester Comprehensive Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Carmen Calfa, MD
      • Miami, Florida, Forenede Stater, 33136
        • Rekruttering
        • University of Miami/Sylvester Cancer Institute - Alex's Place
        • Kontakt:
        • Ledende efterforsker:
          • Carmen Calfa, MD
      • Miami, Florida, Forenede Stater, 33136
        • Rekruttering
        • University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building
        • Kontakt:
        • Ledende efterforsker:
          • Carmen Calfa, MD
      • Miami, Florida, Forenede Stater, 33176
        • Rekruttering
        • University of Miami/Sylvester Cancer Institute - Kendall
        • Kontakt:
        • Ledende efterforsker:
          • Carmen Calfa, MD
      • Miami, Florida, Forenede Stater, 33181
        • Rekruttering
        • University of Miami/Sylvester Cancer Institute - Sole Mia
        • Kontakt:
        • Ledende efterforsker:
          • Carmen Calfa, MD
      • Naples, Florida, Forenede Stater, 34102
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Ocala, Florida, Forenede Stater, 34474
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Orange City, Florida, Forenede Stater, 32763
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Orlando, Florida, Forenede Stater, 32806
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Plantation, Florida, Forenede Stater, 33324
        • Rekruttering
        • University of Miami/Sylvester Cancer Institute - Plantation
        • Kontakt:
        • Ledende efterforsker:
          • Carmen Calfa, MD
      • Port Charlotte, Florida, Forenede Stater, 33980
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Sarasota, Florida, Forenede Stater, 34236
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Sarasota, Florida, Forenede Stater, 34239
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • St. Petersburg, Florida, Forenede Stater, 33701
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Tampa, Florida, Forenede Stater, 33607
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Tavares, Florida, Forenede Stater, 32778
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • The Villages, Florida, Forenede Stater, 32159
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Trinity, Florida, Forenede Stater, 34655
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
      • Venice, Florida, Forenede Stater, 34285
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Venice, Florida, Forenede Stater, 34292
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists South / Sarah Cannon Research Institute
      • Winter Park, Florida, Forenede Stater, 32789
        • Aktiv, ikke rekrutterende
        • Florida Cancer Specialists North / Sarah Cannon Research Institute
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University Winship Cancer Institute
        • Ledende efterforsker:
          • Olatunji Alese, MD
        • Kontakt:
      • Atlanta, Georgia, Forenede Stater, 30265
        • Rekruttering
        • Cancer Treatment Centers of America - Atlanta
        • Ledende efterforsker:
          • Bamidele Adesunloye, MD
        • Kontakt:
          • Elizabeth McKoy, RN, BSN
          • Telefonnummer: 770-400-7177
          • E-mail: emckoy@coh.org
      • Savannah, Georgia, Forenede Stater, 31405
        • Rekruttering
        • Summit Cancer Care
        • Ledende efterforsker:
          • Mark Taylor, MD
        • Kontakt:
      • Savannah, Georgia, Forenede Stater, 31405
        • Rekruttering
        • Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
        • Ledende efterforsker:
          • Mark Taylor, MD
        • Kontakt:
      • Savannah, Georgia, Forenede Stater, 31405
        • Rekruttering
        • Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
        • Ledende efterforsker:
          • Mark Taylor, MD
        • Kontakt:
      • Savannah, Georgia, Forenede Stater, 31405
        • Rekruttering
        • Lewis Cancer & Research Pavilion
        • Kontakt:
          • Stephanie Smith, RN, MSN, OCN
          • Telefonnummer: 912-819-5723
          • E-mail: smiths1@sjchs.org
        • Ledende efterforsker:
          • Mark Taylor, MD
    • Hawaii
      • Honolulu, Hawaii, Forenede Stater, 96813
        • Rekruttering
        • The Queen's Medical Center - POB I
        • Ledende efterforsker:
          • Jared Acoba, MD
        • Kontakt:
      • Honolulu, Hawaii, Forenede Stater, 96813
        • Rekruttering
        • The Queen's Medical Center - Punchbowl
        • Ledende efterforsker:
          • Jared Acoba, MD
        • Kontakt:
      • Honolulu, Hawaii, Forenede Stater, 96817
        • Rekruttering
        • The Queen's Medical Center - Kuakini
        • Ledende efterforsker:
          • Jared Acoba, MD
        • Kontakt:
      • ‘Ewa Beach, Hawaii, Forenede Stater, 96706
        • Rekruttering
        • The Queen's Medical Center - West Oahu
        • Ledende efterforsker:
          • Jared Acoba, MD
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60099
        • Rekruttering
        • Cancer Treatment Centers of America-Chicago
        • Ledende efterforsker:
          • Evan Pisick, MD
        • Kontakt:
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46250
        • Rekruttering
        • Community Health Network (The University of Texas MD Anderson Cancer Center)
        • Ledende efterforsker:
          • Funda Meric-Bernstam, MD
        • Kontakt:
    • Maine
      • Augusta, Maine, Forenede Stater, 04330
        • Rekruttering
        • Harold Alfond Center for Cancer Care
        • Kontakt:
        • Ledende efterforsker:
          • Lindsay Hathaway, MD
      • Augusta, Maine, Forenede Stater, 04330
        • Rekruttering
        • Jackson Laboratory - Maine Cancer Genomics Initiative
        • Kontakt:
        • Ledende efterforsker:
          • Jens Rueter, MD
      • Belfast, Maine, Forenede Stater, 04915
        • Rekruttering
        • Waldo County General Hospital
        • Ledende efterforsker:
          • Roger Inhorn, MD
        • Kontakt:
          • Jen - Dalton, MHA, BSN, RN
          • Telefonnummer: 2072948291
          • E-mail: JDalton@mmc.org
      • Biddeford, Maine, Forenede Stater, 04005
        • Rekruttering
        • SMHC Cancer Care and Blood Disorders -Biddeford
        • Ledende efterforsker:
          • Roger Inhorn, MD
        • Kontakt:
      • Brewer, Maine, Forenede Stater, 04412
        • Rekruttering
        • Northern Light Cancer Care
        • Ledende efterforsker:
          • Sarah Sinclair, MD
        • Kontakt:
      • Brewer, Maine, Forenede Stater, 04412
        • Rekruttering
        • Raish Peavey Haskell Children's Cancer and Treatment Center
        • Ledende efterforsker:
          • Sarah Sinclair, MD
        • Kontakt:
      • Brunswick, Maine, Forenede Stater, 04011
        • Rekruttering
        • MaineHealth Cancer Care -Brunswick
        • Ledende efterforsker:
          • Roger Inhorn, MD
        • Kontakt:
          • Jen - Dalton, MHA, BSN, RN
          • Telefonnummer: 2072948291
          • E-mail: JDalton@mmc.org
      • Kennebunk, Maine, Forenede Stater, 04043
        • Rekruttering
        • New England Cancer Specialist
        • Ledende efterforsker:
          • Christian Thomas, MD
        • Kontakt:
      • Kittery, Maine, Forenede Stater, 03904
        • Rekruttering
        • York Hopsital Oncology & Infusion Care in Kittery
        • Ledende efterforsker:
          • Marilyn McLaughlin, MD
        • Kontakt:
      • Norway, Maine, Forenede Stater, 04268
        • Rekruttering
        • Stephens Memorial Hospital
        • Ledende efterforsker:
          • Roger Inhorn, MD
        • Kontakt:
          • Jen - Dalton, MHA, BSN, RN
          • Telefonnummer: 2072948291
          • E-mail: JDalton@mmc.org
      • Rockport, Maine, Forenede Stater, 04856
        • Rekruttering
        • Penobscot Bay Medical Center
        • Ledende efterforsker:
          • Roger Inhorn, MD
        • Kontakt:
          • Jen - Dalton, MHA, BSN, RN
          • Telefonnummer: 2072948291
          • E-mail: JDalton@mmc.org
      • Sanford, Maine, Forenede Stater, 04073
        • Rekruttering
        • SMHC Cancer Care and Blood Disorders -Sandford
        • Ledende efterforsker:
          • Roger Inhorn, MD
        • Kontakt:
          • Jen - Dalton, MHA, BSN, RN
          • Telefonnummer: 2072948291
          • E-mail: JDalton@mmc.org
      • Scarborough, Maine, Forenede Stater, 04074
        • Rekruttering
        • Maine Children's Cancer Program
        • Ledende efterforsker:
          • Roger Inhorn, MD
        • Kontakt:
          • Jen - Dalton, MHA, BSN, RN
          • Telefonnummer: 2072948291
          • E-mail: JDalton@mmc.org
      • Scarborough, Maine, Forenede Stater, 04074
        • Rekruttering
        • Maine Medical Partner's Women's Health
        • Ledende efterforsker:
          • Roger Inhorn, MD
        • Kontakt:
          • Jen - Dalton, MHA, BSN, RN
          • Telefonnummer: 2072948291
          • E-mail: JDalton@mmc.org
      • Scarborough, Maine, Forenede Stater, 04074
        • Rekruttering
        • New England Cancer Specialist
        • Ledende efterforsker:
          • Christian Thomas, MD
        • Kontakt:
      • South Portland, Maine, Forenede Stater, 04106
        • Rekruttering
        • MaineHealth Cancer Care -South Portland
        • Kontakt:
          • Jen Dalton, MHA, BSN, RN
          • Telefonnummer: 207-294-8291
          • E-mail: JDalton@mmc.org
        • Ledende efterforsker:
          • Roger Inhorn, MD
      • Topsham, Maine, Forenede Stater, 04086
        • Rekruttering
        • New England Cancer Specialist
        • Ledende efterforsker:
          • Christian Thomas, MD
        • Kontakt:
      • Wells, Maine, Forenede Stater, 04090
        • Rekruttering
        • York Hospital Oncology & Infusion Care in Wells
        • Ledende efterforsker:
          • Marilyn McLaughlin, MD
        • Kontakt:
      • York Village, Maine, Forenede Stater, 03909
        • Rekruttering
        • York Hospital Oncology & Infusion Care in York
        • Ledende efterforsker:
          • Marilyn McLaughlin, MD
        • Kontakt:
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • Aktiv, ikke rekrutterende
        • University of Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48106
      • Detroit, Michigan, Forenede Stater, 48236
      • Flint, Michigan, Forenede Stater, 48503
      • Grand Rapids, Michigan, Forenede Stater, 49503
        • Rekruttering
        • Cancer Research Consortium of West Michigan
        • Kontakt:
        • Ledende efterforsker:
          • Kathleen J. Yost, MD
      • Lansing, Michigan, Forenede Stater, 48912
      • Livonia, Michigan, Forenede Stater, 48154
      • Pontiac, Michigan, Forenede Stater, 48341
      • Saginaw, Michigan, Forenede Stater, 48601
      • Traverse City, Michigan, Forenede Stater, 48341
        • Rekruttering
        • Michigan Cancer Research Consortium
        • Ledende efterforsker:
          • Philip Stella, MD
        • Kontakt:
        • Kontakt:
          • Telefonnummer: 877-590-5995
      • Warren, Michigan, Forenede Stater, 48093
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68198
        • Rekruttering
        • University of Nebraska Medical Center
        • Ledende efterforsker:
          • Alissa Marr, MD
        • Kontakt:
    • New Hampshire
      • Concord, New Hampshire, Forenede Stater, 03103
        • Rekruttering
        • NH Oncology - Hematology, PA
        • Kontakt:
        • Ledende efterforsker:
          • Michael Buff, MD
      • Manchester, New Hampshire, Forenede Stater, 03103
        • Rekruttering
        • Solinsky Center for Cancer Care
        • Kontakt:
        • Ledende efterforsker:
          • Michael Buff, MD
      • Portsmouth, New Hampshire, Forenede Stater, 03801
        • Rekruttering
        • New England Cancer Specialist
        • Ledende efterforsker:
          • Christian Thomas, MD
        • Kontakt:
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87110
        • Rekruttering
        • Presbyterian Kaseman Hospital
        • Ledende efterforsker:
          • Bernard Tawfik, MD
        • Kontakt:
      • Albuquerque, New Mexico, Forenede Stater, 87102
        • Rekruttering
        • Lovelace Medical Center - Saint Joseph Square
        • Ledende efterforsker:
          • Bernard Tawfik, MD
        • Kontakt:
      • Albuquerque, New Mexico, Forenede Stater, 87131
        • Rekruttering
        • The University of New Mexico Comprehensive Cancer Center
        • Ledende efterforsker:
          • Bernard Tawfik, MD
        • Kontakt:
      • Las Cruces, New Mexico, Forenede Stater, 88011
        • Rekruttering
        • Memorial Medical Center
        • Ledende efterforsker:
          • Bernard Tawfik, MD
        • Kontakt:
      • Rio Rancho, New Mexico, Forenede Stater, 87124
        • Rekruttering
        • Presbyterian Rust Medical Center
        • Ledende efterforsker:
          • Bernard Tawfik, MD
        • Kontakt:
    • New York
      • Lake Success, New York, Forenede Stater, 11042
        • Rekruttering
        • Northwell Health Monter Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Marina Frimer, MD
      • Mount Kisco, New York, Forenede Stater, 10549
        • Rekruttering
        • Northern Westchester Hospital
        • Ledende efterforsker:
          • Marina Frimer, MD
        • Kontakt:
      • New Hyde Park, New York, Forenede Stater, 11040
        • Rekruttering
        • Cohen Children's Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Marina Frimer, MD
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Manhattan Eye, Ear, and Throat Hospital
        • Ledende efterforsker:
          • Marina Frimer, MD
        • Kontakt:
      • New York, New York, Forenede Stater, 10305
        • Rekruttering
        • Staten Island University Hospital
        • Ledende efterforsker:
          • Marina Frimer, MD
        • Kontakt:
        • Kontakt:
      • Rego Park, New York, Forenede Stater, 11374
        • Rekruttering
        • Queens Cancer Center
        • Ledende efterforsker:
          • Marina Frimer, MD
        • Kontakt:
      • Sleepy Hollow, New York, Forenede Stater, 10591
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27599
        • Rekruttering
        • Lineberger Comprehensive Cancer Center
        • Ledende efterforsker:
          • Shetal Patel, MD
        • Kontakt:
      • Charlotte, North Carolina, Forenede Stater, 28277
        • Rekruttering
        • Atrium Health's Levine Cancer Institute
        • Ledende efterforsker:
          • Kathryn F. Mileham, MD, FACP
        • Kontakt:
    • North Dakota
      • Bismarck, North Dakota, Forenede Stater, 58501
        • Rekruttering
        • Sanford Health- Bismarck
        • Kontakt:
        • Ledende efterforsker:
          • Peter Kurniali, MD
      • Fargo, North Dakota, Forenede Stater, 58122
        • Rekruttering
        • Sanford Health- Fargo
        • Kontakt:
        • Ledende efterforsker:
          • Anu Gaba, MD
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45219
        • Rekruttering
        • University of Cincinnati Medical Center
        • Ledende efterforsker:
          • Davendra Sohal, MD
        • Kontakt:
      • Kettering, Ohio, Forenede Stater, 45429
        • Rekruttering
        • Kettering Health
        • Kontakt:
        • Ledende efterforsker:
          • Lex Leonhardt, DO
      • West Chester, Ohio, Forenede Stater, 45069
        • Rekruttering
        • West Chester Hospital
        • Ledende efterforsker:
          • Trisha Wise-Draper, MD
        • Kontakt:
    • Oregon
      • Portland, Oregon, Forenede Stater, 97213
        • Rekruttering
        • Providence Health & Services
        • Ledende efterforsker:
          • Evthokia Hobbs, MD
        • Kontakt:
    • Pennsylvania
      • Allentown, Pennsylvania, Forenede Stater, 18103
      • Bethlehem, Pennsylvania, Forenede Stater, 18017
      • East Stroudsburg, Pennsylvania, Forenede Stater, 18301
      • Hazleton, Pennsylvania, Forenede Stater, 18201
      • Philadelphia, Pennsylvania, Forenede Stater, 19111
        • Rekruttering
        • Fox Chase Cancer Center
        • Ledende efterforsker:
          • Margaret von Mehren, MD
        • Kontakt:
    • South Carolina
      • Bluffton, South Carolina, Forenede Stater, 29910
        • Rekruttering
        • SC Cancer Specialists at St. Joseph's/Candler Bluffton
        • Ledende efterforsker:
          • Mark Taylor, MD
        • Kontakt:
      • Bluffton, South Carolina, Forenede Stater, 29910
        • Rekruttering
        • St. Joseph's/Candler Smith
        • Ledende efterforsker:
          • Mark Taylor, MD
        • Kontakt:
      • Bluffton, South Carolina, Forenede Stater, 29910
        • Rekruttering
        • Summit Cancer Care at St. Josph's/Candler Bluffton
        • Ledende efterforsker:
          • Mark Taylor, MD
        • Kontakt:
      • Hilton Head Island, South Carolina, Forenede Stater, 29926
        • Rekruttering
        • South Carolina Cancer Specialists
        • Ledende efterforsker:
          • Mark Taylor, MD
        • Kontakt:
    • South Dakota
      • Sioux Falls, South Dakota, Forenede Stater, 57104
        • Rekruttering
        • Sanford Cancer Center Oncology Clinic and Pharmacy
        • Ledende efterforsker:
          • Steven Powell, MD
        • Kontakt:
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • Tennessee Oncology - Nashville / Sarah Cannon Research Institute
        • Kontakt:
        • Ledende efterforsker:
          • Meredith McKean, MD, MPH
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • The University of Texas MD Anderson Cancer Center
        • Ledende efterforsker:
          • Funda Meric-Bernstam, MD
        • Kontakt:
    • Utah
      • Cedar City, Utah, Forenede Stater, 84720
        • Rekruttering
        • Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
        • Ledende efterforsker:
          • Ramya Thota, MD
        • Kontakt:
        • Ledende efterforsker:
          • Derrick Haslem, MD
      • Salt Lake City, Utah, Forenede Stater, 84107
        • Rekruttering
        • Intermountain Healthcare
        • Kontakt:
        • Ledende efterforsker:
          • Ramya Thota, M.D.
        • Ledende efterforsker:
          • Derrick Haslem, M.D.
      • St. George, Utah, Forenede Stater, 84770
        • Rekruttering
        • Dixie Regional Medical Center-River Road Campus
        • Ledende efterforsker:
          • Ramya Thota, MD
        • Kontakt:
        • Ledende efterforsker:
          • Derrick Haslem, MD
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22042
        • Rekruttering
        • Inova Schar Cancer Institute
        • Ledende efterforsker:
          • Timothy Cannon, MD
        • Kontakt:
    • Washington
      • Bonney Lake, Washington, Forenede Stater, 98391
        • Rekruttering
        • Northwest Medical Specialties
        • Kontakt:
        • Ledende efterforsker:
          • Frank Senecal, MD
      • Federal Way, Washington, Forenede Stater, 98003
        • Rekruttering
        • Northwest Medical Specialties
        • Kontakt:
        • Ledende efterforsker:
          • Frank Senecal, MD
      • Gig Harbor, Washington, Forenede Stater, 98332
        • Rekruttering
        • Northwest Medical Specialties
        • Kontakt:
        • Ledende efterforsker:
          • Frank Senecal, MD
      • Olympia, Washington, Forenede Stater, 98502
        • Rekruttering
        • Northwest Medical Specialties
        • Kontakt:
        • Ledende efterforsker:
          • Frank Senecal, MD
      • Puyallup, Washington, Forenede Stater, 98373
        • Rekruttering
        • Northwest Medical Specialties
        • Ledende efterforsker:
          • Frank Senecal, MD
        • Kontakt:
      • Seattle, Washington, Forenede Stater, 98104
        • Rekruttering
        • Swedish Cancer Institute
        • Ledende efterforsker:
          • Philip Gold, MD
        • Kontakt:
      • Tacoma, Washington, Forenede Stater, 98405
        • Rekruttering
        • Northwest Medical Specialties
        • Ledende efterforsker:
          • Frank Senecal, MD
        • Kontakt:
    • Wisconsin
      • Burlington, Wisconsin, Forenede Stater, 53105
        • Rekruttering
        • Aurora Cancer Care - Burlington
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Germantown, Wisconsin, Forenede Stater, 53022
        • Rekruttering
        • Aurora Health Care - Germantown Health Center
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Grafton, Wisconsin, Forenede Stater, 53024
        • Rekruttering
        • Aurora Cancer Care - Grafton
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Green Bay, Wisconsin, Forenede Stater, 54311
        • Rekruttering
        • Aurora BayCare Medical Center
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Kenosha, Wisconsin, Forenede Stater, 53142
        • Rekruttering
        • Aurora Cancer Care - Kenosha South
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Marinette, Wisconsin, Forenede Stater, 54143
        • Rekruttering
        • Aurora Bay Area Medical Center
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Milwaukee, Wisconsin, Forenede Stater, 53215
        • Rekruttering
        • Aurora St. Luke's Medical Center
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Milwaukee, Wisconsin, Forenede Stater, 53209
        • Rekruttering
        • Aurora Cancer Care Milwaukee
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Milwaukee, Wisconsin, Forenede Stater, 53223
        • Rekruttering
        • Aurora Sinai Medical Center
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Milwaukee, Wisconsin, Forenede Stater, 53227
        • Rekruttering
        • Aurora West Allis Medical Center
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Oshkosh, Wisconsin, Forenede Stater, 54904
        • Rekruttering
        • Vince Lombardi Cancer Clinic - Oshkosh
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Racine, Wisconsin, Forenede Stater, 53406
        • Rekruttering
        • Aurora Cancer Care - Racine
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Sheboygan, Wisconsin, Forenede Stater, 53081
        • Rekruttering
        • Vince Lombardi Cancer Center
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Summit, Wisconsin, Forenede Stater, 53066
        • Rekruttering
        • Aurora Medical Center in Summit
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Two Rivers, Wisconsin, Forenede Stater, 54241
        • Rekruttering
        • Vince Lombardi Cancer Clinic - Two Rivers
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
      • Wauwatosa, Wisconsin, Forenede Stater, 53226
        • Rekruttering
        • Aurora Cancer Care - Milwaukee West
        • Ledende efterforsker:
          • Antony Ruggeri, MD
        • Kontakt:
    • Puerto Rico
      • Cayey, Puerto Rico, Puerto Rico, 00737
      • Dorado, Puerto Rico, Puerto Rico, 00646
      • Manati, Puerto Rico, Puerto Rico, 00674
      • Mayagüez, Puerto Rico, Puerto Rico, 00680
      • Ponce, Puerto Rico, Puerto Rico, 00730
      • San Juan, Puerto Rico, Puerto Rico, 00909
      • San Juan, Puerto Rico, Puerto Rico, 00935

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • 12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)

  • Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication).

  • Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)

  • Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:

    1. Absolute neutrophil count ≥ 1500 µl
    2. Hemoglobin ≥ 9.0 g/dl
    3. Platelets ≥ 75,000/µl
    4. Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
    5. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
    6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
  • Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma).

  • Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.

  • Ability to understand and the willingness to sign a written informed consent/assent document.

  • Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.

  • For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.

  • Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse.

Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.

Exclusion Criteria:

  • Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
  • Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded
  • Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
  • Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.

Note: there are additional exclusion criteria that may apply

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: Group 5 (CSF1R,PDGFR,VEGFR)

Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations

drug

Andre navne:
  • Sutent
Andet: Group 8 (ERBB2)

Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations

drug

Andre navne:
  • Herceptin og Perjeta
Andet: Group 9 (BRAF V600E/D/K/R)

Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations

drug

Andre navne:
  • Zelboraf og Cotellic
Andet: Group 14 (BRCA1/2; ATM)

Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions

drug

Andre navne:
  • Lynparza
Andet: Group 16 (MSI-H, high mutational load and others)

Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations

drug

Andre navne:
  • Opdivo og Yervoy
Andet: Group 17 (CDKN2A, CDK4, CDK6)

Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation

drug

Andre navne:
  • Verzenio
Andet: Group 19 (BRCA1/2, PALB2)

Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations

drug

Andre navne:
  • Talzenna
Andet: Group 21 (BRCA1/2, PALB2, ATM, and others)

Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval

drug

Andre navne:
  • Tecentriq og Talzenna
Andet: Group 24 (ERBB2)

Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations

drug

Andre navne:
  • Tukysa og Herceptin Hylecta
Andet: Group 25

Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation

drug

Andre navne:
  • Lytgobi
Andet: Group 26 (BRAF V600 E mutation )

Participants receive Dabrafenib plus Trametinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600 E mutation .

Drug

Andre navne:
  • Mekinist
  • tanfinlar
Andet: Group 27 (ERBB2 amplification, ERBB2 (HER2) IHC2+ or IHC3+ overexpression)

Participants receive Fam-trastuzumab deruxtecan-nxki (ENHERTU®) - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification, For NSCLC Only-ERBB2 (HER2) IHC2+ or IHC3+ overexpression without ERBB2 amplification)

Drug

Andre navne:
  • Enhertu

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Tidsramme: Assessed at 16 weeks of treatment

Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.

Assessed at 16 weeks of treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall survival (OS)
Tidsramme: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years

OS will be estimated using the Kaplan-Meier method

Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

14. marts 2016

Primær færdiggørelse (Anslået)

31. december 2027

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

11. februar 2016

Først indsendt, der opfyldte QC-kriterier

23. februar 2016

Først opslået (Anslået)

26. februar 2016

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. september 2026

Sidst verificeret

1. september 2026

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner